DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Wegovy (semaglutide, weekly) outperforms Saxenda (liraglutide, daily) on both weight loss and convenience. Saxenda is the only GLP-1 FDA-approved for ages 12-17.
Wegovy (semaglutide, weekly) outperforms Saxenda (liraglutide, daily) on both weight loss and convenience. Saxenda is the only GLP-1 FDA-approved for ages 12-17.
Direct comparison: Wegovy delivers ~15% body weight loss vs Saxenda ~8% at 56 weeks. Once-weekly injection vs daily — most patients prefer weekly. Cost is similar (both ~$1,349 retail; both have $25 commercial savings card). The exception: pediatric weight loss. Saxenda is the only GLP-1 FDA-approved for adolescents 12-17 with obesity. Adults should default к Wegovy unless daily-injection preference, Saxenda intolerance history, or pediatric pathway.